&nbsp;

Feb 2025

Drug

degarelix

Other Name(s): Firmagon®

Quick Link(s):

Feb 2025

Drug

dacarbazine

Quick Link(s):

Jun 2025

Drug

denosumab

Other Name(s): Xgeva®; Wyost™; Osenvelt™

Quick Link(s):

Dec 2025

Drug

daBRAFenib

Other Name(s): Tafinlar®

Quick Link(s):

Jun 2025

Drug

osimertinib

Other Name(s): Tagrisso®

Quick Link(s):

Nov 2025

Regimen

DASA

Cancer Type:

Hematologic,

Leukemia - Chronic Myeloid (CML)

Intent: Palliative

Funding:

Exceptional Access Program

daSAtinib - Ph+ CML in the chronic phase, with specific criteria

Exceptional Access Program

daSAtinib - Accelerated phase or blast phase Ph+ CML with documented resistance or intolerance to imatinib, with specific criteria

Drugs Used:

daSATinib

Quick Link(s):

Regimen Monograph

Feb 2025

Regimen

DCRB

Cancer Type:

Sarcoma,

Soft Tissue,

Skin,

Melanoma

Intent: Palliative

Drugs Used:

dacarbazine

Quick Link(s):

Regimen Monograph

Jun 2025

Regimen

DCTN

Cancer Type:

Gynecologic,

Gestational Trophoblastic Disease

Intent: Curative

Drugs Used:

DACTINomycin

Quick Link(s):

Regimen Monograph

Dec 2025

Regimen

DGRL

Cancer Type:

Genitourinary,

Prostate

Intent: Adjuvant, Palliative

Funding:

ODB - General Benefit

degarelix

Drugs Used:

degarelix